Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit MeetingGlobeNewsWire • 05/19/22
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual MeetingGlobeNewsWire • 04/27/22
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023GlobeNewsWire • 03/30/22
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/10/22
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate DevelopmentsGlobeNewsWire • 11/11/21
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual MeetingGlobeNewsWire • 11/01/21
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS ConferenceGlobeNewsWire • 09/30/21
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDGlobeNewsWire • 09/28/21
Graybug Vision to Participate in the Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/21/21
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate DevelopmentsGlobeNewsWire • 08/11/21
Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/21
Is the Options Market Predicting a Spike in Graybug Vision (GRAY) Stock?Zacks Investment Research • 06/16/21
Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMDBenzinga • 05/12/21
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/12/21